Clinical Pharmacology: An Annotated Bibliography of Recent Literature
Authors: CLINICAL PHARMACOLOGY COMMITTEE
Journal: Annals of Internal Medicine (1982)

The Literature of Medicine1 September 1982Clinical Pharmacology: An Annotated Bibliography of Recent LiteratureReferences to Journal Articles and Other PapersCLINICAL PHARMACOLOGY COMMITTEECLINICAL PHARMACOLOGY COMMITTEESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-3-465 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis bibliography includes references to 35 recently published journal papers and similar sources that represent important developments in the concept and practice of internal medicine. It has been compiled by the Clinical Pharmacology Committee* as part of the Medical Knowledge Self-Assessment Program VI Syllabus.In preparing this bibliography, the committee reviewed MEDLINE† bibliographic printouts of journal articles published since the beginning of 1978 and also drew on sources in libraries of hospitals and other clinical institutions in the United States and Canada; thus, only papers in English are listed, and most are from American journals....Use of Plasma Concentration Measurements Principles of Dose Selection APPLICATION OF PHARMACOKINETIC CONCEPTS BIOAVAILABILITY OF DRUGS Individualization of Drug Therapy DOSE ADJUSTMENT IN PATIENTS WITH IMPAIRED RENAL FUNCTION THERAPY WITH DRUGS ELIMINATED PRIMARILY BY METABOLISM ALTERATIONS IN DRUG DISTRIBUTION Alteration in Drug Receptors During Chronic Therapy Drug Therapy of Elderly Patients1. DUHMEGREENBLATTKOCH-WESER DDJ. Reduction of digoxin toxicity associated with measurement of serum levels. Ann Intern Med. 1974;80:516-9. Prospective study showing that measuring serum digoxin levels reduces the incidence of digoxin toxicity. LinkGoogle Scholar2. KOCH-WESER J. Serum drug concentrations as therapeutic guides. N Engl J Med. 1972;287:227-31. Discussion of the clinical use of plasma level measurements of drugs. CrossrefMedlineGoogle Scholar3. LATINIBONATITOGNONI RMG. Clinical role of blood levels. Ther Drug Monitor. 1980;2:3-9. Recent summary of the current status and future challenges of therapeutic drug monitoring. CrossrefMedlineGoogle Scholar4. ATKINSON A. Individualization of anticonvulsant therapy. Med Clin North Am. 1974;585:1037-49. Review of therapeutic concentration ranges, pharmacokinetics, and metabolism of selected anticonvulsant drugs. CrossrefGoogle Scholar5. ATKINSON A. Lidocaine and procainamide therapy of ventricular arrhythmias: a clinical pharmacological perspective. In: MELMON KL, ed. Drug Therapeutics: Concepts for Physicians. New York: Elsevier; 1981:17-33. Analysis of lidocaine and procainamide therapy with respect to the pharmacokinetics and known active metabolites of these drugs. Google Scholar6. ATKINSONKUSHNER AW. Clinical pharmacokinetics. Annu Rev Pharmacol Toxicol. 1979;19:105-27. Review of basic pharmacokinetic principles. CrossrefMedlineGoogle Scholar7. KOCH-WESER J. Bioavailability of drugs. N Engl J Med 1974;291:233-7, 503-6. Review of basic concepts of drug absorption, bioavailability and bioequivalence. CrossrefMedlineGoogle Scholar8. LINDENBAUMMELLOWBLACKSTONEBUTLER JMMV. Variation in biologic availability of digoxin from four preparations. N Engl J Med 1971;285:1344-7. Classic report of clinically important differences in the bioavailability of four digoxin formulations. CrossrefMedlineGoogle Scholar9. NIMMO W. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1:189-203. The relation between gastric emptying and drug absorption is described; previous notions about the importance of the gastric absorption of drugs are dispelled. CrossrefMedlineGoogle Scholar10. BENETSHEINER LL. Design and optimization of dosage regimens: pharmacokinetic data. In: GILMAN AG, GOODMAN LS, GILMAN A, eds. The Pharmacologic Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co.; 1980:1675-1737. Authoritative compendium of the basic pharmacokinetic parameters of 98 commonly used drugs. Google Scholar11. BENNETTMUTHERPARKER WRR. Drug therapy in renal failure: dosing guidelines for adults. Ann Intern Med. 1980;93:62-89, 286-325. Summary of drug modifications for patients with impaired renal function. LinkGoogle Scholar12. DETTLI L. Individualization of drug dosage in patients with renal disease. Med Clin North Am. 1974;58(5):977-85. Presentation of a general nomographic method for adjusting drug dosage for patients with impaired renal function. CrossrefMedlineGoogle Scholar13. JELLIFFEBOOKER RG. A nomogram for digoxin therapy. Am J Med. 1974;57:63-8. Description of an empirically derived nomogram for adjusting daily digoxin doses for patients with impaired renal function. CrossrefMedlineGoogle Scholar14. REIDENBERG M. The biotransformation of drugs in renal failure. Am J Med. 1977;62:482-5. Review of the effects of renal failure on the rate of drug metabolism by the liver. CrossrefMedlineGoogle Scholar15. ATKINSONSTECLERTORARUOTHENOT AGJTJ. Impact of active metabolites on monitoring plasma concentrations of therapeutic drugs. Ther Drug Monitor. 1980;2:19-27. Analysis of the contributions of the active metabolites of lidocaine and procainamide to the therapeutic and toxic responses of patients treated with these drugs. CrossrefMedlineGoogle Scholar16. DRAYER D. Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet. 1976;1:426-43. Review of drugs that have pharmacologically active metabolites. CrossrefMedlineGoogle Scholar17. HANSENKENNEDYAMBREFISCHER AKJL. Glutethimide poisoning: a metabolite contributes to morbidity and mortality. N Engl J Med. 1975;292:250-2. Analysis of the effects of glutethimide and its more potent hydroxylated metabolite in a comatose patient who ingested glutethimide. CrossrefMedlineGoogle Scholar18. HENDELESWEINBERGERJOHNSON LMG. Monitoring serum theophylline levels. Clin Pharmacokinet. 1978;3:294-312. Review of current recommendations for interpreting theophylline plasma level measurements and for estimating appropriate theophylline dosage in different patient groups. CrossrefMedlineGoogle Scholar19. MITCHELLJOLLOWS JD. Metabolic activation of drugs to toxic substances. Gastroenterology. 1975;68:392-410. Review of adverse reactions caused by the covalent binding of reactive drug metabolites to tissue macromolecules. CrossrefMedlineGoogle Scholar20. WILKINSONSHAND GD. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377-90. Exposition of hepatic clearance concepts that provide the basis for classifying drugs as restrictively or nonrestrictively eliminated by the liver. CrossrefMedlineGoogle Scholar21. ZWILLICHSUTTONNEFFCOHNMATTHAYWEINBERGER CFTWRM. Theophylline-induced seizures in adults: correlation with serum concentrations. Ann Intern Med. 1975;82:784-7. Eight patients developed seizures while receiving intravenous theophylline therapy. Four of these patients never regained consciousness and died. LinkGoogle Scholar22. BOOKERDARCEY HB. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia. 1973;14:177-84. Analysis of the relationship between clinical response and free concentration of phenytoin not bound to serum proteins. CrossrefMedlineGoogle Scholar23. GUGLERSHOEMANHUFFMANCOHLMIAAZARNOFF RDDJD. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest. 1975;55:1182-9. In patients with the nephrotic syndrome phenytoin kinetics are altered in a manner consistent with the observed reduction in plasma protein binding from 89.9% in normal subjects to 80.8% in the patients. CrossrefMedlineGoogle Scholar24. RANGNO R. Stopping beta-blockers in patients with angina. Ration Drug Ther. 1981;15(9):1-4. Review of the mechanism underlying the propranolol withdrawal syndrome with recommendations for clinical management of patients with angina in whom propranolol therapy must be stopped. MedlineGoogle Scholar25. Tardive dyskinesia [Editorial]. Lancet. 1979;2:447-8. Brief review of mechanisms proposed for tardive dyskinesia with guidelines for attempting to prevent this syndrome in patients requiring neuroleptic therapy. MedlineGoogle Scholar33. COCKCROFTGAULT DM. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. Presentation of an equation for estimating creatinine clearance from serum creatinine, weight, and age. CrossrefMedlineGoogle Scholar34. KAMPMANNSIERSBAEK-NIELSENKRISTENSENMØLHOLM HANSEN JKMJ. Rapid evaluation of creatinine clearance. Acta Med Scand. 1974;196:517-20. Evaluation of a standard nomogram for estimating creatinine clearance from serum creatinine, weight, and age. CrossrefMedlineGoogle Scholar35. REIDENBERG M. Drugs in the elderly. Bull NY Acad Med. 1980;56:703-14. Overview of drug therapy in elderly patients. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Arthur J. Atkinson, Jr., M.D., Chairman; Marcus M. Reidenberg, M.D.; and W. Leigh Thompson, Jr., M.D.†Computer literature-file of the National Library of Medicine, Bethesda, Maryland, consulted through the Regional Medical Library service of the College of Physicians of Philadelphia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug-Nutrient InteractionsPATRICK J. KEARNS, M.D. 1 September 1982Volume 97, Issue 3Page: 465-466KeywordsClinical pharmacologyComputersLibraries ePublished: 1 December 2008 Issue Published: 1 September 1982 Copyright & Permissions©1982 American College of PhysiciansPDF downloadLoading ...